Las Vegas, NV -- (SBWIRE) -- 12/20/2013 -- (Tech Sonian) - EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Solta Medical Inc (NASDAQ:SLTM), Oncothyreon Inc (USA) (NASDAQ:ONTY), Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) managed to keep its gain at 4.67% on above-normal volume of 1.08M shares. The stock settled at $4.93 after floating in a range of $4.85 to $4.96. Its latest price has reached market capitalization of $299.87 million. Its 52-week range has been $2.41 to $6.47. Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers.
For How Long PGNX will fight for Profitability? Read This Trend Analysis report
Solta Medical Inc (NASDAQ:SLTM) traded up on a volume of 1.08 million, lower than its standard daily volume. Shares have gained 0.34% to $2.94. Over the last twelve months, the stock has gained 12.21% and faced a worst price of $1.44. Solta Medical, Inc. designs, develops, manufactures and markets professional and consumer energy-based medical device systems for aesthetic applications. The Company's systems are cleared by the United States Food and Drug Administration (FDA) for dermatological procedures performed in the physician led, professional assist, and personal care markets.
For How Long SLTM’s Gloss will Attract Investors? Find out via this report
Oncothyreon Inc (USA) (NASDAQ:ONTY) settled 2.31% higher at $1.77 on above-normal volume of 1.06M shares during the last trading day. The stock has its 12-month high at $2.81 and 52-week low price was $1.55. It traded in a range of $1.69 to $1.85 during the last trading day. Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer.
Why Should Investors Buy ONTY After the Recent Fall? Just Go Here and Find Out
In the last trading session, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) was up on low volume, trading at a volume of 1.06M versus its average daily volume of 1.29 million shares. At $0.440, the stock has attained market capitalization of 64.56 million. Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company’s pipeline features one drug candidate in Phase II clinical trials.
Will RNN Continue To Move Higher? Find Out Here
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)